🎉 M&A multiples are live!
Check it out!

Enlivex Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Enlivex Therapeutics and similar public comparables like Pharming, Vivoryon Therapeutics, and Galapagos.

Enlivex Therapeutics Overview

About Enlivex Therapeutics

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.


Founded

2012

HQ

United States of America
Employees

49

Website

enlivex.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

-$2.0M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Enlivex Therapeutics Financials

Enlivex Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Enlivex Therapeutics achieved revenue of n/a and an EBITDA of -$24.3M.

Enlivex Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Enlivex Therapeutics valuation multiples based on analyst estimates

Enlivex Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$25.0M -$24.3M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$14.5M -$31.1M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Enlivex Therapeutics Stock Performance

As of April 15, 2025, Enlivex Therapeutics's stock price is $1.

Enlivex Therapeutics has current market cap of $21.0M, and EV of -$2.0M.

See Enlivex Therapeutics trading valuation data

Enlivex Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$2.0M $21.0M XXX XXX XXX XXX $-0.63

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Enlivex Therapeutics Valuation Multiples

As of April 15, 2025, Enlivex Therapeutics has market cap of $21.0M and EV of -$2.0M.

Enlivex Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Enlivex Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Enlivex Therapeutics and 10K+ public comps

Enlivex Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$2.0M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 0.1x XXX XXX XXX
P/E -0.7x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.1x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Enlivex Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Enlivex Therapeutics Valuation Multiples

Enlivex Therapeutics's NTM/LTM revenue growth is n/a

Enlivex Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.5M for the same period.

Over next 12 months, Enlivex Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Enlivex Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Enlivex Therapeutics and other 10K+ public comps

Enlivex Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -3% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $0.5M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Enlivex Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Enlivex Therapeutics M&A and Investment Activity

Enlivex Therapeutics acquired  XXX companies to date.

Last acquisition by Enlivex Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Enlivex Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Enlivex Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Enlivex Therapeutics

When was Enlivex Therapeutics founded? Enlivex Therapeutics was founded in 2012.
Where is Enlivex Therapeutics headquartered? Enlivex Therapeutics is headquartered in United States of America.
How many employees does Enlivex Therapeutics have? As of today, Enlivex Therapeutics has 49 employees.
Who is the CEO of Enlivex Therapeutics? Enlivex Therapeutics's CEO is Mr. Oren Hershkovitz, PhD.
Is Enlivex Therapeutics publicy listed? Yes, Enlivex Therapeutics is a public company listed on NAS.
What is the stock symbol of Enlivex Therapeutics? Enlivex Therapeutics trades under ENLV ticker.
When did Enlivex Therapeutics go public? Enlivex Therapeutics went public in 2014.
Who are competitors of Enlivex Therapeutics? Similar companies to Enlivex Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Enlivex Therapeutics? Enlivex Therapeutics's current market cap is $21.0M
Is Enlivex Therapeutics profitable? Yes, Enlivex Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.